Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 3 completed trials

    Completion Rate
    100%(3/3)
    Active Trials
    0(0%)
    Results Posted
    33%(1 trials)

    Phase Distribution

    Phase 1/2
    3
    75%

    Phase Distribution

    0

    Early Stage

    3

    Mid Stage

    0

    Late Stage

    Phase Distribution3 total trials
    Phase 1/2Combined phases
    3(100.0%)

    Highest Phase Reached

    Phase 1/2

    Trial Status & Enrollment

    Completion Rate

    100.0%

    3 of 3 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    4

    all time

    Status Distribution
    Completed(3)
    Other(1)

    Detailed Status

    Completed3
    unknown1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    4
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 1/2

    Trials by Phase

    Phase 1/23 (100.0%)

    Trials by Status

    unknown125%
    completed375%

    Recent Activity

    0 active trials
    Showing 4 of 4
    unknown

    Islet Transplant for Type 1 or Surgical Diabetes

    NCT01606475
    completedphase_1_2

    MGA031, Sirolimus and Tacrolimus in Islet Transplantation

    NCT00265473
    completedphase_1_2

    hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients

    NCT00285194
    completedphase_1_2

    Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation

    NCT00286624

    Clinical Trials (4)

    Showing 4 of 4 trials
    NCT01606475

    Islet Transplant for Type 1 or Surgical Diabetes

    Unknown
    NCT00265473Phase 1/2

    MGA031, Sirolimus and Tacrolimus in Islet Transplantation

    Completed
    NCT00285194Phase 1/2

    hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients

    Completed
    NCT00286624Phase 1/2

    Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation

    Completed

    All 4 trials loaded

    Drug Details

    Intervention Type
    Varies by study
    Total Trials
    4